治疗因子-Xa抑制剂相关出血与安德克森特阿尔法或4因子PCC:一个多中心可行性追溯研究
Adam J Singer1, Mauricio Concha2, James Williams3
1Renaissance School of Medicine at Stony Brook University, Department of Emergency Medicine, Stony Brook, New York, adam.singer@stonybrook.edu.
The western journal of emergency medicine
|October 3, 2023
概括
这项研究发现,收集XA因子抑制剂 (FXa-I) 出血的患者数据是可行的. 虽然安德xanet alfa显示出比4F-PCC (4F-PCC) 更好的结果的趋势,但样本规模较小限制了最终的结论.
科学领域:
- 医学研究 医学研究
- 临床试验中的临床试验.
- 药理学 药理学是指药理学的学科.
背景情况:
- 没有随机试验比较FXa-I出血的Andexanet alfa和4F-PCC.
- 观察性研究往往缺乏关键的患者特征.
- 电子健康记录 (EHR) 可以促进对比研究的数据采集.
研究的目的:
- 为了证明从EHR收集FXa-I相关出血的详细患者特征的可行性.
- 其次,在患有危及生命的FXa-I相关出血的患者中,探索和比较安德克萨内特α和4F-PCC之间的结果.
主要方法:
- 对100名患有FXa-I相关的脑内出血或胃肠道出血的成年患者的多中心图表综述.
- 患者接受了安德克萨尼特阿尔法或4F-PCC治疗.
- 收集的数据包括人口统计,临床状况,实验室,成像和FXa-I剂量和出血发作的时间.
主要成果:
- 平均年龄为75岁;34%是女性. 在76%的病例中,从最后一次FXa-I剂量到出血开始的时间可用.
- 安德克萨尼特阿尔法的血静效率为88%,而4F-PCC的效率为76% (P=0.29).
- 90天的血栓事件分别为14%和16% (P=0.80),存活到出院的时间分别为92%和76% (P=0.25).
结论:
- 从电子健康记录中收集重要患者特征的可行性得到证实,支持更大的观察性研究.
- 当前研究的样本规模很小,因此无法得出关于安德克萨内特阿尔法与4F-PCC对FXa-I相关出血的安全性和有效性的最终结论.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
8.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14


